Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CNR2 | P34972 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL579788 | 0.85 | LMNA (0.40) | LMNAALDH1A1MAPK1TSHRCYP3A4 | |
| SCHEMBL29365165 | 0.85 | LMNA (0.40) | LMNAALDH1A1MAPK1TSHRCYP3A4 | |
| SCHEMBL1704092 | 0.83 | LMNA (0.35) | LMNAALDH1A1MAPK1TSHRCYP3A4 | |
| SCHEMBL7217044 | 0.82 | LMNA (0.42) | LMNAALDH1A1MAPK1TSHRCYP3A4 | |
| SCHEMBL268986 | 0.79 | LMNA (0.36) | LMNAALDH1A1MAPK1TSHRCYP3A4 | |
| SCHEMBL18979221 | 0.79 | LMNA (0.40) | LMNAALDH1A1MAPK1TSHRCYP3A4 | |
| SCHEMBL28638598 | 0.79 | LMNA (0.40) | LMNAALDH1A1MAPK1TSHRCYP3A4 | |
| SCHEMBL27481297 | 0.79 | LMNA (0.40) | LMNAALDH1A1MAPK1TSHRCYP3A4 | |
| SCHEMBL473811 | 0.78 | LMNA (0.41) | LMNAALDH1A1MAPK1TSHRMEN1 | |
| SCHEMBL30111341 | 0.78 | LMNA (0.41) | LMNAALDH1A1MAPK1TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220000762-A1 | COMPOSITIONS FOR TREATING OXIDATIVE STRESS-ASSOCIATED SKIN DISEASES AND SKIN AGEING AND DIAGNOSIS OF OXIDATIVE STRESS-ASSOCIATED SKIN DISEASES | S-biomedic N.v. (BE) | 2022-01-06 | — | — | US | disclosed |
| EP-3880304-A1 | COMPOSITIONS FOR TREATING OXIDATIVE STRESS-ASSOCIATED SKIN DISEASES AND SKIN AGEING AND DIAGNOSIS OF OXIDATIVE STRESS-ASSOCIATED SKIN DISEASES | S-Biomedic NV (BE) | 2021-09-22 | — | — | EP | disclosed |
| CN-113038959-A | Composition for treating oxidative stress-related skin diseases and skin aging and diagnosis of oxidative stress-related skin diseases | S-生物医药有限公司 | 2021-06-25 | — | — | CN | disclosed |
| WO-2020099663-A1 | COMPOSITIONS FOR TREATING OXIDATIVE STRESS-ASSOCIATED SKIN DISEASES AND SKIN AGEING AND DIAGNOSIS OF OXIDATIVE STRESS-ASSOCIATED SKIN DISEASES | S-biomedic N.v. (BE) | 2020-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000762-A1 | COMPOSITIONS FOR TREATING OXIDATIVE STRESS-ASSOCIATED SKIN DISEASES AND SKIN AGEING AND DIAGNOSIS OF OXIDATIVE STRESS-ASSOCIATED SKIN DISEASES | CUTA, LPO, PPOX | LMNA 2240/4885ALDH1A1 1640/4885MAPK1 3298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.